News

ZORYVE® Foam Receives FDA Approval for Plaque Psoriasis Care

ZORYVE® Foam Receives FDA Approval for Plaque Psoriasis Care

FDA Approves ZORYVE® Foam for Plaque Psoriasis Treatment

In an exciting development for those suffering from plaque psoriasis, Arcutis Biotherapeutics, Inc. has achieved a significant milestone with the recent FDA approval of its innovative ZORYVE® (roflumilast) topical foam 0.3%. This breakthrough treatment is now an available option for individuals aged 12 and older grappling with this chronic inflammatory skin condition.

Benefits of ZORYVE Foam

ZORYVE foam is designed to be applied once daily, delivering powerful clearance of psoriatic plaques while also relieving itching effectively. This flexibility means patients can use the treatment over extended periods without any limitations. For many patients, especially those afflicted with scalp involvement—over half of the nearly 9 million individuals with plaque psoriasis in the U.S.—this convenience is revolutionary.

Flexibility in Treatment Options

Healthcare providers can choose between two formulations of ZORYVE: the foam and cream, enabling tailored treatments suitable for various areas of the body where psoriasis may appear. The foam is particularly advantageous for treating difficult areas like the scalp, face, and other hair-covered locations, where traditional creams can be cumbersome to use.

Clinical Effectiveness and Safety Profile

Clinical trials have painted a promising picture for the effectiveness of ZORYVE foam. The results met all efficacy endpoints, showing significant improvements in the signs and symptoms of psoriasis for patients. ZORYVE foam has not only been credited with effectively clearing plaques but has also been recognized for offering rapid relief from itching—a symptom that greatly impacts the quality of life for many patients.

Expert Insights on Treatment Challenges

Dr. Jennifer Soung, a clinical researcher, articulated the challenges of treating plaque psoriasis in sensitive areas and underscored the foam's benefits. "A safe and effective foam offers a much-needed solution for patients who struggle with managing psoriasis in hard-to-treat areas. The comprehensive approach with ZORYVE foam means treating the entire body with one formulation, easing the treatment regimen significantly," she noted.

Arcutis’ Commitment to Innovation

Frank Watanabe, Arcutis' president and CEO, expressed the company’s dedication to developing solutions that best meet patient needs. He pointed out that ZORYVE foam provides long-term relief, and its approval reflects Arcutis' mission to supply individuals suffering from chronic inflammatory skin conditions with impactful treatment options. This latest approval marks the fifth for ZORYVE within a span of just three years, highlighting the company’s commitment to advancing care in dermatology.

Improving Quality of Life for Patients

Living with plaque psoriasis can severely affect a person's mental and emotional well-being. Leah Howard from the National Psoriasis Foundation remarked on the importance of effective treatments and how innovations like ZORYVE foam can bring significant relief to those affected by psoriasis, particularly when lesions are visible on the scalp or face.

Accessibility and Support Programs

ZORYVE foam is not only widely available but is supported by the ZORYVE® Direct Program, helping patients navigate insurance processes and adhere to their treatment plans. This program is designed to reduce out-of-pocket expenses for patients who meet certain eligibility criteria. Additionally, Arcutis is committed to community support through its Arcutis Cares™ program, which offers ZORYVE at no cost for eligible uninsured or underinsured patients.

Conclusion and Future Directions

As Arcutis continues its journey in dermatological innovation, the approval of ZORYVE foam represents a crucial advancement in psoriasis care. With promising clinical data, flexible use, and strong community support initiatives, Arcutis is positioning itself as a leader in addressing the pressing needs of patients living with plaque psoriasis.

Frequently Asked Questions

What is ZORYVE® foam and what condition does it treat?

ZORYVE® foam is a topical treatment for plaque psoriasis approved for use in patients aged 12 and older, offering effective relief from visible lesions and itch.

How often should ZORYVE foam be applied?

ZORYVE foam is designed for once-daily application, promoting convenience in managing plaque psoriasis.

Are there any common side effects of ZORYVE foam?

Common adverse reactions may include headache, nausea, and diarrhea. Most side effects are mild to moderate.

Is patient support available for those using ZORYVE?

Yes, Arcutis provides patient assistance programs including the ZORYVE® Direct Program and Arcutis Cares™, which help patients access their medications at reduced costs.

How does ZORYVE foam differ from other psoriasis treatments?

ZORYVE foam is steroid-free and uniquely formulated for convenient application on sensitive and hard-to-treat areas, including the scalp.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading